Clinical Trials Logo

Clinical Trial Summary

Psoriasis and metabolic disorders are well-known mutual comorbidities. The investigators hypothesized metformin can ameliorate both psoriasis and metabolic disorders mainly via gut microbiota modulation. The investigators design a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment of metformin for psoriasis combined with disorders of glucose and lipid metabolism and to explore the role of gut microbiota during the process.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03629639
Study type Interventional
Source Central South University
Contact Yi Xiao, M.D
Phone +8618674823326
Email xiaoy26@uw.edu
Status Not yet recruiting
Phase Phase 4
Start date September 1, 2018
Completion date December 1, 2020